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Abstract
Background: Tuberous sclerosis complex (TSC) is an autosomal dominant neurogenetic disorder caused by
mutations in one of two genes, TSC1 or TSC2, which encode the proteins hamartin and tuberin, respectively [1-3].
Common features of TSC include intractable epilepsy, mental retardation, and autistic features. TSC is associated
with specific brain lesions, including cortical tubers, subependymal nodules and subependymal giant cell
astrocytomas. In addition, this disease frequently produces characteristic tumors, termed hamartomas, in the
kidneys, heart, skin, retina, and lungs. Disease severity in TSC can be quite variable and is not determined by the
primary mutation alone. In fact, there is often considerable variability in phenotype within single families, where all
affected individuals carry the same mutation. Factors suspected to influence phenotype in TSC include the specific
primary mutation, random occurrence of second-hit somatic mutations, mosaicism, “modifying genes”, and
environmental factors. In addition to these factors, we hypothesize that differences in mRNA expression from the
non-mutated TSC allele, or possibly from the mutated allele, play a part in modifying disease severity. Common
genetic variants that regulate mRNA expression have previously been shown to play important roles in human
phenotypic variability, including disease susceptibility. A prediction based on this idea is that common regulatory
variants that influence disease severity in TSC should be detectable in non-affected individuals.
Methods: A PCR/primer extension assay was used to measure allele specific expression of TSC1 and TSC2 mRNAs
in leukocytes isolated from normal volunteers. This assay can be used to measure “allelic expression imbalance”
(AEI) in individuals by making use of heterozygous “marker” single nucleotide polymorphisms (SNPs) located within
their mRNA.
Results: In this study we show for the first time that TSC1 and TSC2 genes exhibit allele-specific differences in
mRNA expression in blood leukocytes isolated from normal individuals.
Conclusions: These results support the possibility that allele-specific variation in TSC mRNA expression contributes
to the variable severity of symptoms in TSC patients.
Background
Tuberous sclerosis complex (TSC) is an autosomal
dominant neurogenetic disease caused by a mutation in
either the TSC1 or TSC2 gene [1-3]. Roughly two-thirds
of TSC cases reported in mutational and epidemiologi-
cal studies are sporadic (simplex), while the remaining
cases are familial [4-9]. Neurological symptoms include
seizures, cognitive delay, impulsivity, attention deficit,
and learning disabilities. TSC patients often present with
characteristic brain lesions, including cortical tubers,
subependymal nodules (SENs), and subependymal giant
cell astrocytomas (SEGAs). The severity of neurological
symptoms is variable, although mental retardation and
intractable epilepsy are fairly common and are fre-
quently the most debilitating symptoms [2,10,11].
Lesions outside of the nervous system, including renal
angiomyolipomas (AMLs), renal cysts, cardiac rhabdomyo-
mas, facial angiofibromas, periungual fibromas, retinal
hamartomas, and pulmonary lymphangioleiomyomas
(LAM), are also characteristic of TSC [2,11]. Some of
these lesions may result in life threatening events, such as
hemorrhage into a large AML [12,13] or spontaneous
pneumothorax or chylothorax from a ruptured LAM [14].
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TSC are likely to be caused by loss of heterozygosity
(LOH) due to a “second-hit” mutation that compromises
the remaining normal TSC allele. This has been demon-
strated in renal AMLs, cardiac rhabdomyomas, SEGAs
and SENs [13,15-18]. By contrast, LOH has only rarely
been demonstrated in cortical tubers [19,20]. While the
lesions of TSC are generally associated with LOH, cog-
nitive symptoms, including mental retardation, hyperac-
tivity, impulsivity and attention deficit, may occur by a
different mechanism, likely involving haploinsufficiency
of TSC proteins in brain cells. In fact, the pathway in
which hamartin and tuberin function has been shown to
influence both neuronal structure and function [21]. It
is therefore plausible that dysregulation of this pathway
(a quantitative effect) produces cognitive deficits.
Studies of coding and splice region mutations of the
TSC1 and TSC2 genes have not yet produced a clear
understanding of the relationship between genotype and
phenotype, as people with the same primary mutation
often have very different phenotypic outcomes [22,23]. It
is generally accepted, however, that mutations in the
TSC1 gene produce milder symptoms compared to
mutations in the TSC2 gene [4,5,9,24]. Although most
studies have failed to consistently link specific mutations
to distinct phenotypes, there are exceptions such as the
TSC2 R905Q mutation, which produces a mild form of
the disease, and the TSC2 R905W and R905G mutations,
which are associated with more severe forms of TSC [25].
Our research is aimed at understanding why indivi-
duals carrying identical TSC gene mutations often have
widely varying clinical outcomes. It has been repeatedly
noted in the literature that phenotypic variation of TSC
disease is very common within families [2,26-31]. The
reason for this intra-familial variability in phenotype is
currently unknown, although potential explanations
include the modifying effects of unlinked genes, epige-
netic factors [32,33], or mosaicism [34,35].
In many simple genetic disorders, pathogenic mutations
inactivate the encoded protein or reduce its quantity or
stability, thereby leading to an inadequate level of func-
tional protein in the cell. TSC is an autosomal dominant
genetic disease and, consequently, affected individuals are
heterozygous for mutations in TSC1 or TSC2, i.e., one
mutant and one normal allele is present in each cell [1-3].
We hypothesize that the differential expression of normal
and mutant alleles may account for some proportion of
the observed phenotypic variation. For example, it is possi-
ble that at the cellular level, relatively high levels of expres-
sion of the normal allele may compensate for the
abnormal protein produced by the mutant allele. Conver-
sely, high expression of a “gain of function” mutant pro-
tein, such as a mutant with dominant-negative properties,
may be particularly deleterious. Based upon these
considerations, it is plausible that allele-specific cis-acting
elements that regulate mRNA expression [36-39] contri-
bute to differences in disease severity in TSC.
If common regulatory elements within the TSC loci
p l a yar o l ei nm o d u l a t i n gd i s e a s ep h e n o t y p ei ni n d i v i -
duals carrying a mutation at one of the TSC genes, we
would expect to be able to detect the same regulatory
elements in subjects selected from the normal popula-
tion. To test this hypothesis we used a PCR/primer
extension-based assay to measure allele-specific differ-
ences in expression of TSC1 and TSC2 mRNAs in leu-
kocytes isolated from normal volunteers. The use of this
assay allows highly accurate measurements of “allelic
expression imbalance” (AEI) for individuals who are het-
erozygous for a “marker” single nucleotide polymorph-
ism (SNP) located within the mRNA. Based on these
measurements, we estimate that about 19% of the popu-
lation (our sample group was of mixed races with a pre-
dominance of Caucasian individuals) is heterozygous for
high- and low-expression alleles at the TSC1 locus and
10% of the population is heterozygous for high- and
low-expression alleles at the TSC2 locus.
Methods
IRB Approval
This research was approved by the St. Joseph’s Hospital
and Medical Center Institutional Review Board (IRB) for
Human Research. Informed consent was obtained from
all study participants. Participants were healthy volun-
teers who denied any personal or familial history of
Tuberous Sclerosis Complex.
Isolation of DNA and RNA from blood samples
DNA was extracted from blood leukocytes using Gentra
Puregene Blood Kits (Qiagen, Valencia, California) and
stored at 4°C. RNA was extracted from blood leukocytes
using PAXgene Blood RNA Kits (Qiagen, Valencia, Cali-
fornia) and stored at -80°C.
cDNA Synthesis from RNA samples
TSC1 (NM_000368) and TSC2 (NM_000548) mRNAs
were reverse-transcribed to cDNA using gene-specific
primers and the SuperScript III First-Strand synthesis
system for RT-PCR, according to the manufacturer’s
protocol (Invitrogen, Carlsbad, California). The cDNA
synthesis primer sequence for TSC1 mRNA was 5’-GGG
CCTGTGCTGACTCTGGTTAGTG-3’. The sequence of
the cDNA synthesis primer for TSC2 mRNA was 5’-TT
TCACTGACAGGCAATACC-3’. cDNAs were stored at
-20°C.
Selection of Coding Region SNPs in TSC1 and TSC2
To distinguish TSC gene alleles we chose marker SNPs
with relatively high rates of heterozygosity, as indicated
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http://www.ncbi.nlm.nih.gov, the SNPper resource
(CHIP Bioinformatics resource - http://snpper.chip.org)
and by our own genotyping data. Due to the need to
distinguish the alleles, only samples heterozygous at
marker SNPs were analyzed. Two SNPs were chosen as
markers for TSC1 alleles: rs739442 (C/T) and rs2809243
(C/T), both located in the 3’-untranslated region (UTR)
of TSC1 mRNA. The DNA samples were genotyped at
several exonic SNPs in the TSC2 gene. One synonymous
SNP located within exon 40, rs1748 (C/T), proved to
have the highest rate of heterozygosity among the tested
SNPs (~24%) and was therefore used for AEI analysis.
Together, these three marker SNPs tag all known TSC1
and TSC2 mRNA splice variants.
Genotyping using the SNaPshot assay
All samples were genotyped using the SNaPshot assay.
This method of genotyping relies on the presence of
heterozygous marker SNPs to distinguish between two
alleles of a gene. In homozygous samples, where the
gene alleles have the same nucleotide at the SNP locus,
electropherograms will show a single peak using the for-
ward primer and a single peak using the reverse primer.
In heterozygous samples, the presence of different
nucleotides at the SNP locus on each allele will result in
the production of two peaks in both forward and reverse
reactions.
PCR primer pairs were designed for amplifying geno-
mic DNA segments that included each SNP of interest.
The amplimer segments were used in a SNaPshot assay
(ABI Prism SNaPshot Multiplex Kit) to establish the
genotype (homozygous versus heterozygous) of indivi-
duals at each of the marker SNPs. The primers for
amplifying the 3’UTR genomic DNA segment containing
the TSC1 SNPs rs2809243 and rs739442 (amplimer
size = 587 bp) were: 5’-TAGTAATGGCAGAGCAGTC-
TAA ACA-3’ (forward) and 5’-TCCAGGTCTCATTCT
CCCAACCGTA-3’ (reverse). The primers for amplifying
a genomic DNA segment surrounding TSC2 exon 40
were: 5’-CTGGGCAACGACTTTGTGTCCATTGTC-
TAC-3’ (forward) and 5’-CTGACAGGCAATACCGTC-
CAA-3’ (reverse). This primer pair produces an 1857 bp
amplimer when used with genomic DNA. The PCR pro-
gram consisted of an initial denaturation at 94°C for 40
seconds. This was followed by 40 cycles of 94°C for 20
seconds, 55°C for 1 minute, 72°C for 1 1/2 minutes, and
a final extension step at 72°C for 5 minutes. PCR pro-
ducts were gel purified from 1-1.5% low melt agarose
gels (IBI Scientific, Peosta, Iowa) using the Wizard PCR
Preps DNA Purification System (Promega, Madison,
Wisconsin).
Genotyping was done with primers designed for
SNaPshot analysis. The SNaPshot assay was performed
according to the manufacturer’s protocol (Applied Bios-
ciences, Inc.). Briefly, a PCR reaction was run in which
a single fluorescently-tagged dideoxynucleotide was
a d d e da tt h e3 ’-end of an annealed primer that was
designed to terminate exactly one nucleotide before the
SNP of interest (different fluorophores for ddA, ddG,
ddC, and ddT). This allowed the identity of the SNP
nucleotide to be determined using a capillary sequencer
(Applied Biosystems Inc. Prism 310 Genetic Analyzer).
This assay was used both for genotyping individuals at
various SNPs and for AEI determination (as described
in the following section). While both forward and
reverse primers can be used for this analysis, the for-
ward primers for each of the SNPs analyzed were found
to give cleaner, more reliable results and were thus used
in this assay.
The primers for SNaPshot analysis of the TSC1 gene
alleles were: rs2809243 5’-AAACTCAACAAGTGCTCC
TGAAAGAAA-3’ (forward) and rs739442 5’-TACGA
AATCTTAGTGCC-3’ (forward). The primer for SNaP-
shot analysis of the TSC2 gene allele was rs1748 (for-
ward): 5’-GCATCATAGCCGCTCCAACCCCACCGA-3’.
The PCR program consisted of 25 cycles of a 96°C dena-
turation step for 10 seconds, 50°C for 5 seconds and 60°C
for 30 seconds. Subsequently, samples were treated for
45 minutes at 37°C with 5 units of antarctic phosphatase
(New England Biolabs, Ipswich, Massachusetts). The
phosphatase was then inactivated by incubating at 65°C
for 10 minutes. Samples were run on the capillary
sequencer and the genotype determined from the electro-
pherogram generated during the run.
Allelic expression imbalance assay
Samples heterozygous at marker SNPs were tested for
AEI using the SNaPshot assay. Genomic and cDNA
fragments flanking each SNP (as described above) were
amplified in triplicate and gel purified. The same pri-
mers previously described for use in the amplification of
genomic DNA segments were used in this assay to
amplify TSC1 and TSC2 cDNA gene segments. The pri-
mer pair amplifying the TSC2 cDNA segment produces
a 553 bp fragment when used with cDNA rather than
the 1857 bp fragment produced with genomic DNA as
the template. This is due to inclusion of intronic
sequence in the PCR product from genomic DNA. The
PCR reactions amplify both alleles, preserving the exist-
ing allele ratios in genomic DNA and in cDNA. The
concentrations of gel purified samples (purification per-
formed as indicated above) were measured using a
Nanodrop 2000c (Thermo Scientific, Waltham, Massa-
chusetts). Equal concentrations of the amplified frag-
ments were then used in SNaPshot assays. All genomic
and cDNA samples were analyzed in triplicate using the
ABI capillary sequencer.
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due to differences in the detection efficiency of various
fluorophores, this ratio often deviates from 1.0. Therefore,
genomic DNA was used as an internal control to correct
for the differences in detection. In order to calculate the
necessary correction factor, the genomic DNA allelic ratios
for a specific SNP from each capillary sequencer run were
averaged and the correction factor was calculated as the
inverse of this average genomic allelic ratio. A diagram of
the method used for calculating and applying the correc-
tion factor is shown in Figure 1. The allele ratios for geno-
mic and cDNA samples were calculated as the ratio of
heterozygous peak heights (analysis done using Gene
Mapper 3.0 software from Applied Biosystems, Inc.). The
experimental values for both the genomic DNA and the
cDNA were then multiplied by the correction factor and
average values were calculated for each sample analyzed in
triplicate (see Results section for additional details). Stan-
dard error of the mean (SEM) was calculated for each
sample using Excel software (Microsoft, Inc.) and error
bars indicating 2X SEM were used in graphing the results.
Results
AEI was examined in the TSC1 and TSC2 genes by
quantifying the relative amounts of mRNA derived from
each of the two alleles of each gene in leukocyte RNA
samples isolated from normal individuals heterozygous
for mRNA marker SNPs. To avoid the confounding
effects of alternative splicing, SNPs located within the
3’-UTR of the TSC1 g e n ea n di ne x o n4 0o ft h eTSC2
gene were selected as markers. These regions are
included in all known mRNA forms generated from the
TSC1 and TSC2 genes. The rs numbers (NCBI SNP
data base, http://www.ncbi.nlm.nih.gov/snp) and loca-
tions of the three TSC1 and TSC2 marker SNPs used in
this study are shown in Figure 2.
As described in detail in Methods, our AEI assays
involve PCR amplification of short segments of TSC1 or
TSC2 cDNA containing a marker SNP, followed by
annealing of a synthetic oligonucleotide primer to a site
immediately upstream from the SNP and primer exten-
sion in the presence of fluorescently tagged dideoxynu-
cleotide triphosphates (ddNTPs). Because each ddNTP
Figure 1 Method for correcting genomic and cDNA allele ratios (AR). Genomic DNA segments containing marker SNPs are amplified by
PCR and used as templates in SNaPshot primer-extension assays. Extended primers containing one of two different fluorescently labeled
nucleotides at their 3’-ends are resolved by capillary electrophoresis and the ratio of peak heights calculated. An average genomic AR for a
specific SNP is determined from all the genomic samples (each analyzed in triplicate). A correction factor (CF) is then calculated as the inverse of
the average genomic AR. The genomic samples analyzed in triplicate are then individually multiplied by the CF to normalize the data to
approximately 1.0, which is the theoretical ratio of two gene alleles in genomic DNA. The corrected average genomic AR is then determined. For
each RNA sample, cDNA is synthesized and heterozygous SNP containing segments are amplified by PCR in triplicate and subjected to a
SNaPshot PCR reaction. Samples are run on a capillary sequencer and the ratio of heterozygous peak heights is determined. Individual cDNA ARs
are calculated and corrected by multiplying by the CF. The average corrected cDNA AR for each sample is then calculated. A sample is
designated as showing AEI if the average corrected genomic AR and average corrected cDNA AR differ by greater than 2X the standard error of
the mean and by at least 10%.
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added base can be determined by resolving the fluores-
cently labeled primers by capillary electrophoresis and
identifying the “color” of each extended primer [40].
Differences in expression between two alleles can be
quantified by calculating the ratio of the peak heights of
the traces corresponding to each fluorescently labeled
primer. To correct for artifactual imbalances related to
technical aspects of the assay, AEI assays were also car-
ried out using genomic DNA, which in the absence of
local chromosome deletions or duplications, would be
expected to contain equal numbers of each allele. A cor-
rection factor derived from these measurements was
used to correct AEI measurements obtained using
cDNA templates.
SNP frequencies in the sample population
Our assay uses SNPs located within protein coding
exons or the 3’-UTR to distinguish between the mRNA
species that are transcribed from the two alleles of a
gene in each individual. Because only subjects who are
heterozygous at marker SNPs are informative in our
assays, we first genotyped our subjects to identify indivi-
duals who are heterozygous for one or more of the
TSC1 and TSC2 marker SNPs described above. The het-
erozygosities of the TSC1 markers rs2809243 and
rs739442 were approximately 49% (41/83) and 45% (37/
83), respectively, in our sample. Heterozygosity of the
TSC2 marker SNP rs1748 was approximately 22% (18/
82). These data are similar to average population hetero-
zygosities for subjects of all races reported for these
SNPs on the SNPper website (CHIP Bioinformatics
resource - http://snpper.chip.org) and the NCBI SNP
database. Approximately 36% (30/83) of subjects were
heterozygous at both TSC1 SNPs.
AEI in the TSC1 gene
AEI analysis of TSC1 mRNA expression was performed
independently using the marker SNPs rs2809243 and
rs739442. As indicated above, 41 individuals were het-
erozygous at rs2809243 and 37 were heterozygous at
rs739442. 30 individuals were heterozygous at both of
the marker SNPs. Data from these doubly heterozygous
individuals was used for independent validation of the
results from each SNP. As outlined in Figure 1, AEI
measurements using genomic DNA as template were
carried out to permit the calculation of a correction fac-
tor for AEI measurements using cDNA as template.
AEIs were considered to be significant if the corrected
cDNA allelic expression ratio differed from the cor-
rected genomic allele ratio by greater than 10%, and if
the error bars (defined here as 2x the standard error of
the mean) for the average genomic and cDNA allele
ratios did not overlap.
Figure 3 displays the corrected genomic and cDNA
AEI ratios for each individual in our sample. Shown to
the left in each graph is the data for individuals hetero-
zygous at both marker SNPs. Shown to the right in each
graph is additional data for individuals heterozygous at a
single marker SNP. 8/41 individuals show AEI using
rs2809243 while 7/37 individuals show AEI using
rs739442. Of the doubly heterozygous individuals,
rs2809243 revealed 6 individuals with AEI reaching our
defined level of significance while rs739442 showed 5
individuals demonstrating AEI. The 5 individuals with
AEI by rs739442 were the same as those with AEI by
rs2809243. A 6
th individual’s sample (#11) reached AEI
significance by a small margin using rs2809243 but did
not reach significance using rs739442 as the marker
SNP, thus emphasizing the importance of using a sec-
ond SNP to validate data. We were able to consistently
Figure 2 This diagram shows the exon/intron structure of the TSC1 and TSC2 genes. Exons are represented by numbered boxes. Exons
subject to alternative splicing are indicated by brackets. The locations of the SNPs used for analysis of AEI are indicated by stars.
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AEI in blood leukocytes using two different SNPs. The
AEI of TSC1 mRNA expression in this control group
ranged from 10% to greater than 30%. While this degree
of imbalance is relatively small, it could be sufficient to
modulate the phenotype in a TSC patient heterozygous
for a mutation in the TSC1 gene. Based on this small
cohort of control subjects we estimate that the
population frequency of AEI at the TSC1 locus may be
as high as 15-20%.
It should be noted that the cDNA allelic expression
ratios measured using the marker SNP rs280943 range
from greater that 1 (samples 29 and 36) to less than 1
(samples 3 and 27). This implies that the regulatory var-
iant or variants resulting in this AEI are not tightly
linked to the marker SNP. Thus, if these individuals
Figure 3 AEI analysis of TSC1 mRNA expression in leukocytes isolated from 30 individuals doubly heterozygous for the marker SNPs
rs2809243 and rs739442 and additional individuals (11 and 7 individuals respectively) singly heterozygous for one of the two SNPs.
For doubly heterozygous individuals (data at the left side of graphs 3A and 3B), blue bars indicate corrected genomic allelic ratios (AR) and grey
bars indicate the corrected cDNA ARs. Data for singly heterozygous individuals is located to the right side of the 3A and 3B graphs using red
and green bars to indicate genomic ARs and shaded bars to indicate cDNA ARs. Error bars indicate 2X the standard error of the mean (SEM).
Stars indicate samples for which the average corrected cDNA AR differed from the genomic AR by more than 10% and had error bars that did
not overlap with those of the genomic DNA.
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comprising one high-expression allele and one low-
expression allele, the results of our AEI measurements
imply that the high-expression allele is “in phase” (ie.,
located on the same chromosome) with the rs280943
C-allele in individuals 29 and 36, but is “in-phase” with
the rs280943 T-allele in individuals 3 and 27.
Similar arguments hold for the AEI measurement
obtained using rs739442 as the marker SNP. The fact
that the directions of the measured AEI differ for indivi-
dual #27, depending upon the choice of marker SNP,
implies that the “phase” of the marker SNPs with
respect to the functional variant is different in this indi-
vidual. That is, in this individual the rs739442 C-allele is
located on the same chromosome as the high-expression
allele of the remote regulatory variant. Although the two
SNPs used for these analyses (rs280943 and rs739442)
are separated by only 166 bp, our data indicate that
these SNPs are not tightly linked. As previously indi-
cated, only around 29% of our sample population is het-
erozygous at both TSC1 marker SNPs despite their close
proximity. This is apparent in the data of individual #27
which shows the marker SNPs to be on different chro-
mosomes. Using the Hapmap database http://hapmap.
ncbi.nlm.nih.gov the linkage disequilibrium D’ value for
these SNPs is 0.671, confirming that these SNPs are not
tightly linked despite the small separation distance. As
these two SNPs are both located in the 3’UTR of TSC1,
it is not surprising to see this level of variation as muta-
t i o n si nt h i sa r e aa r el e s sl i k e l yt oa f f e c tt h ep r o t e i n
function.
AEI in the TSC2 gene
Twenty out of 83 individuals in our sample were hetero-
zygous for the TSC2 mRNA marker SNP rs1748, As
shown in Figure 4, 10% (2/20) of these individuals
demonstrated AEI above the 10% cut-off, with a differ-
ence of more than 2x the SEM. An independent marker
SNP was not available for verification; however, AEI
measurements were highly reproducible. Our data
demonstrates that AEI is relatively common in both the
TSC1 and TSC2 genes.
Discussion
There is a growing consensus that cis-acting genetic var-
iants significantly contribute to phenotypic differences
among individuals, including disease risk [36,39,41-45].
Regulatory polymorphisms are one of the predominant
mechanisms by which cis-acting gene regulation has
been found to occur. These polymorphisms, located in
regulatory regions, influence the expression of genes by
affecting transcriptional activation or repression, gener-
ally by altering the DNA binding sites for transcription
factors [36,39,46,47]. In addition, splicing errors,
changes in mRNA stablility, epigenetic modifications
and polymorphic (ACn) microsatellites have also been
implicated in cis-acting gene regulation [36,37,39,46-49].
The best known examples of allele-specific differ-
ences in gene expression have been associated with X-
inactivation [50] or genomic imprinting [51]. However,
allelic variation in expression has also been demon-
strated in non-imprinted genes and this allelic varia-
tion itself can be regulated by cis-acting elements
[36-39]. Variations in allele expression have been pre-
viously linked to disease. For example, allelic variation
in APC (adenomatous polyposis coli) expression plays
a role in predisposition to colon cancer [41]. Allelic
expression imbalance has also been studied in the can-
cer associated genes BRCA1/2 and CDH1 and used to
identify polymorphisms, mutations and other defects
that alter allelic expression and influence disease state
[45,48]. As many genes are active within networks,
variation in the expression of specific gene alleles may
ultimately result in multiple downstream effects within
a network and between related gene networks. This
creates an avenue by which even small differences in
the expression of specific genes can ultimately result in
substantial phenotypic changes [46,47].
It has been noted frequently that disease causing
mutations in families with TSC may produce very few
problems in certain individuals while having cata-
strophic effects in others [2,26-31]. Clearly, there are
additional factors outside of the mutation itself that
affect disease severity. Differences in allele specific
mRNA expression could potentially be one of these dis-
ease modifying factors. It is possible that the overall
amount of normal TSC protein in cells may determine
the severity of the disease phenotype in patients. As
TSC is a disease carried in a heterozygous state [1-3],
some amount of normal TSC protein should be present
in most cells since one normal allele of each TSC gene
is present (the exception being abnormal tissue growths
exhibiting LOH [15-18]). It is possible that higher rela-
tive expression of protein from the normal allele may be
protective, while higher relative expression of abnormal
protein from the mutant allele may have deleterious
effects.
We began to study this issue by determining the fre-
quency of occurrence of AEI of the TSC1 and TSC2
genes in a control population. The intent was to estab-
lish if mRNA expression variation might be common
enough to be a mechanism by which phenotypes are
modified in patients with TSC gene mutations. In a
cohort of normal volunteers we were able to quantify
allele specific expression of the TSC genes in blood
RNA and estimate the frequency of allelic skewing of
expression for these two genes. In our studies we found
that there was significant skewing of allelic expression
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tion and of the TSC2 gene in 10% of our population.
This estimate is based on a small sample of informative
individuals (48 individuals who were heterozygous for a
TSC1 marker SNP and 20 who were heterozygous for a
TSC2 marker SNP). This was a sample of convenience,
but individuals were recruited without bias and should
be representative of the general population. If we
assume a binomial distribution for the occurrence of
AEI in the general population, we can use the exact test
to calculate 95% confidence intervals for the actual
population frequencies of AEI at the TSC1 and TSC2
genes. Based on such calculations, the 95% confidence
interval for prevalence of AEI at TSC1 is 9% to 33% and
for AEI at the TSC2 gene is 1.2% to 32%. These confi-
dence intervals for the estimates for the actual popula-
tion frequencies of AEI at TSC1 and TSC2 can of
course be sharpened with larger sample sizes.
While these are not large proportions, AEI may be
occurring frequently enough to be a potential contribu-
tor to the phenotypic differences in TSC patients. In any
given individual patient within a particular family, the
phenotype could be determined not just by the muta-
tion, but also by SNPs located within regulatory regions
of the TSC genes. In such familial cases of TSC, the
implication is that regulatory SNPs inherited from the
parents in various combinations with the normal and
mutant gene alleles can affect the phenotype of the
child.
The TSC1 and TSC2 gene products, hamartin and
tuberin, function together as a protein complex. There-
fore, mutation of either of the TSC genes results in the
same disease [1,3,52]. The hamartin-tuberin complex is
a modulator of the mTOR signaling pathway, which is
important in the regulation of cell growth. We know
that haploinsufficiency due to mutation of a single TSC
gene allele is sufficient to cause TSC and represents an
approximately 50% loss of the total expression of that
TSC gene [2]. Loss of a single TSC gene allele is suffi-
cient to disrupt neuronal morphology and function in
mouse models [21]. Loss of both alleles of a TSC gene
can result in the formation of hamartomas common to
TSC as is demonstrated by LOH studies [13,15-18].
These points clearly suggest that pathways modulated
Figure 4 AEI analysis of TSC2 mRNA expression in leukocytes isolated from 20 individuals heterozygous for the marker SNP rs1748.
Blue bars indicate corrected genomic allelic ratios (AR) and grey bars indicate corrected cDNA ARs. Error bars indicate 2X the standard error of
the mean (SEM). Stars indicate samples for which the average corrected cDNA AR differed from the average corrected genomic AR by more
than 10% and had error bars (2X SEM) that did not overlap with those of the genomic DNA.
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effects. If a 50% reduction in expression of a TSC gene
is sufficient to cause disease, it is plausible that smaller
variations in expression, such as the 10-30% that we
found in our experiments, might be sufficient to influ-
ence phenotype. In our control sample group, this level
of variation in allelic expression of TSC1 or TSC2 does
not result in a phenotype, as both alleles encode normal
proteins. This degree of variation in mRNA expression
combined with mutation of a TSC gene allele may be
sufficient to influence phenotype either positively or
negatively.
It has previously been reported that a 50% decrease in
the expression of a single allele of the adenomatous
polyposis coli tumor suppressor gene (APC), represent-
ing an overall 25% decrease of APC mRNA expression,
is sufficient to cause the development of familial adeno-
matous polyposis [41]. An additional study of a gene
associated with osteoarthritis (GDF5)d i s c o v e r e dt h a ta
promoter polymorphism which created a small reduc-
tion of the expression of the T allele (less than 27%),
significantly increased individuals susceptibility to devel-
oping osteoarthritis [53]. These reports indicate that
even small variations in allelic expression are important
to disease outcomes. This supports our hypothesis that
v a r i a t i o ni ne x p r e s s i o no ft h eT S Cg e n ea l l e l e s ,p a r t i c u -
larly in the presence of an existing genetic mutation,
may influence disease severity in TSC patients.
Tissue specific expression of genes is an important
consideration when assessing the effects of variation in
allelic expression. A sequence variant in the regulatory
region of a gene might be relevant in some tissues and
not in others, leading to conflicting results in different
tissues [54]. Our study was performed in blood samples
as this is a readily available tissue specimen. It is impor-
tant to determine if allelic expression ratios measured in
peripheral blood correlate with ratios measured in brain
tissue, something that may be done using banked tissue
samples. A difficulty we’ve encountered is the availability
of good-quality matched blood and brain tissue samples
from which intact RNA and DNA can be extracted.
Establishing a correlation between blood and brain
expression levels is especially important as we try to
relate expression of the TSC alleles in blood to severity
of cognitive impairment in patients with TSC. The goal
of our research is to determine if the levels of expres-
sion of mutant and wild-type alleles in patients with
TSC, as measured in peripheral blood, correlates with
phenotypic severity. To this end, we plan to next study
familial cases of TSC, where multiple affected indivi-
duals have the same identical gene mutation, but are
discordant in terms of disease severity. We shall deter-
mine if, in these multiplex families, disease severity is
correlated with skewing of allele specific expression.
Ultimately, we hope to use the combination of mutation
detection and measures of AEI in blood samples to pre-
dict disease severity (at least in relation to cognitive
impairment). Early identification of patients who are at
risk for developing severe disease may allow for aggres-
sive preventive interventions, and may protect the
patient from additional damaging effects of the disease.
Conclusions
We have concluded from our research that variation in
TSC1 and TSC2 gene allele expression is common in
normal individuals, as it was easily detected in a rela-
tively small sample population. It is likely that this varia-
tion in allele expression will also be seen in some
patients carrying TSC gene mutations and may therefore
help to explain the intra-familial variation in disease
severity frequently observed in TSC. These ideas can be
tested in multiplex families that include patients with
TSC that are discordant in disease severity (particularly
cognitive symptoms). After such validation, we might be
able to develop a simple blood test (ratio of wild-type to
mutant TSC mRNA levels) that predicts disease severity
in simplex cases of TSC.
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